Advertisement

Comparative efficacy in red blood cell exchange transfusions with different apheresis machines in patients with sickle cell disease

  • Nurhilal Buyukkurt
  • Ilknur Kozanoğlu
  • Asli Pan Korur
  • Suheyl Asma
  • Mahmut Yeral
  • Soner Solmaz
  • Fatih Kandemir
  • Cigdem Gereklioglu
  • Cagla Sariturk
  • Can Boga
  • Hakan Ozdogu
Original Article

Abstract

The purpose of this study is to compare the efficacy and side effects of two red blood cell exchange (RBCX) transfusion systems in sickle cell disease (SCD). The data is collected retrospectively from the January 2010 to March 2015. 447 RBCX transfusions were performed to 165 patients. Side effects, clinical and technical efficacy were compared in between procedures with Cobe Spectra (CS) and Spectra Optia (SO) systems. Furthermore a subgroup analyses was performed for 40 patients who had RBCX transfusions with both system at least two times. Vasoocclusive crises, preoperative period and foot ulcers (49.6, 13, and 15.2% respectively) were the common indications of RBCX transfusion. While the levels of post-RBCX HbS and the actual fraction of cells remaining (FCRa) were found significantly higher in the SO compared to CS system (p = 0.018 and p = 0.016 respectively), the rate of targeted hemoglobin S (HbS) levels (< 30%) were same in both. The length of procedure and replacement volume were significantly lower in SO compared to CS system (p = 0.025 and 0.044 respectively). Subgroup analyses of 40 patients did not reveal any statistically significant differences regarding post-procedure HbS levels, FCRa levels, replacement volume and procedure duration. The inter-rater correlation coefficient for FCRa was calculated to be 0.82. Serious adverse reactions were not observed from either system. Both systems are efficiently achieved the targeted post-procedure HbS level. The recently introduced SO apheresis system is as effective and safe as the CS system, which has been used for all indications of SCD for years.

Keywords

Sickle cell disease Red blood cell exchange Cobe Spectra Spectra Optia 

Notes

Acknowledgement

We thank to the apheresis unit staff for their cooperation.

Funding

This study was approved by the Institutional Medical and Health Sciences Experimental/Clinical Research Principles and Research Committee (Project No: KA15/148).

Compliance with Ethical Standards

Conflicts of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Serjeant GR (1997) Sickle—cell disease. Lancet 350:725–730CrossRefPubMedGoogle Scholar
  2. 2.
    Eaton WA, Hofrichter J (1987) Hemoglobin S gelation and sickle cell disease. Blood 70:1245–1266PubMedGoogle Scholar
  3. 3.
    Stuart MJ, Nagel RL (2004) Sickle-cell disease. Lancet 364:1343–1360CrossRefPubMedGoogle Scholar
  4. 4.
    Kasar M, Boğa C, Yeral M, Asma S, Kozanoglu I, Ozdogu H (2004) Clinical significance of circulating blood and endothelial cell microparticles in sickle-cell disease. J Thromb Thrombolysis 38:167–175CrossRefGoogle Scholar
  5. 5.
    Koçak R, Alparslan ZN, Agridag G, Baslamisli F, Aksungur PD, Koltas S (1995) The frequency of anaemia, iron deficiency, hemoglobin S and beta thalassemia in the south of Turkey. Eur J Epidemiol 11:181–184CrossRefPubMedGoogle Scholar
  6. 6.
    Hebbel RP (2009) Pathobiology of sickle cell disease. In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop H, Furie B, McGlave P, Shattil SJ (eds) Hematology basic principles and practise, 5th edn. Elsevier, Amsterdam, pp 565–602Google Scholar
  7. 7.
    Wang WC (2009) Sickle cell anemia and other sickling syndromes. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT (eds) Wintrobe’s clinical hematology, Nineth edn. Lippincot Williams and Wilkins, Philadelphia, pp 1038–1082Google Scholar
  8. 8.
    Lal A, Vichinsky EP (2005) Sickle cell disease. In: Hoffbrand AV, Catovsky D, Tuddenham EGD (eds) Postgraduate haematology, 5th edn. Blackwell, Massachusetts, pp 104–118CrossRefGoogle Scholar
  9. 9.
    Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML et al (2013) Guidelines on the use of therapeutic apheresis in clinical practice—evidence based approach from the writing committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 28:145–284CrossRefPubMedGoogle Scholar
  10. 10.
    Kozanoglu I, Boga C, Ozdogu H, Sezgin N, Kizilkilic E, Kural M (2007) Automated red cell exchange procedures in patients with sickle cell disease. Transfus Apher Sci 36:305–312CrossRefPubMedGoogle Scholar
  11. 11.
    Morris CR (2008) Mechanisms of vasculopathy in sickle cell disease and talasemia. Hematol Am Soc Hematol Educ Program 2008:177–185Google Scholar
  12. 12.
    Orimolade EA, Salawu L (2008) Immunohematological characteristics of Nigerian sickle cell disease patients with osteomyelitis. Turk J Hematol 25:145–148Google Scholar
  13. 13.
    Kim HC (2014) Red cell exchange: special focus on sickle cell disease. Hematology 2014:450–456CrossRefPubMedGoogle Scholar
  14. 14.
    Josephson CD, Su LL, Hillyer KL, Hillyer CD (2007) Transfusion in patients with sickle cell disease: a critical review of the literature and transfusion guidelines. Trans Med Rev 21:118–133CrossRefGoogle Scholar
  15. 15.
    Singer ST, Quirolo K, Nishi K, Hackney-Stephens E, Evans C, Vichinsky EP (1999) Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher 14:122–125CrossRefPubMedGoogle Scholar
  16. 16.
    Morrison JC, Morrison FS, Floyd RC, Roberts WE, Hess LW, Wiser WL (1991) Use of continuous flow erythrocytapheresis in pregnant patient with sickle cell disease. J Clin Apher 6:224–229CrossRefPubMedGoogle Scholar
  17. 17.
    Cabibbo S, Fidone C, Garozzo G, Antolino A, Manenti GO, Bennardello F et al (2005) Chronic red blood exchange to prevent clinical complications in sickle cell disease. Transf Apheresis Sci 32:315–321CrossRefGoogle Scholar
  18. 18.
    Ozdogu H, Boga C (2015) Hematopoietic stem cell transplantation in adult sickle cell disease. Turk J Hematol 32:195–205CrossRefGoogle Scholar
  19. 19.
    Quirolo K, Bertolone S, Hassell K, Howard T, King KE, Rhodes DK et al (2015) The evaluation of a new apheresis device for automated red blood cell exchange procedures in patients with sickle cell disease. Transfussion 55:775–781CrossRefGoogle Scholar
  20. 20.
    Poullin P, Sanderson F, Bernit E, Brun M, Berdah Y, Badens C (2016) Comparative evaluation of the depletion-red cell exchange program with the spectra optia and the isovolemic hemodilution-red cell exchange method with cobe spectra in sickle cell disease patients. J Clin Apher 31:429–433CrossRefPubMedGoogle Scholar
  21. 21.
    Perseghin P, Incontri A, Capra M, Pichler H, Witt V (2013) Erythrocyte-exchange with the optia™ cell seperator in patients with sickle-cell disease. J Clin Apher 28:411–415CrossRefPubMedGoogle Scholar
  22. 22.
    Asma S, Kozanoglu I, Tarım E, Sarıturk C, Gereklioglu C, Akdeniz A et al (2015) Prophylactic red blood cell exchange may be beneficial in the management of sickle cell disease in pregnancy. Transfusion 55:36–44CrossRefPubMedGoogle Scholar
  23. 23.
    Boga C, Kozanoglu I, Ozdogu H, Sozer O, Sezgin N, Bakar C (2010) Alterations of circulating endothelial cells after apheresis in patients with sickle cell disease: a potential clue of pathophysiology. Transfus Apher Sci 43:273–279CrossRefPubMedGoogle Scholar
  24. 24.
    Boga C, Ozdogu H, Kozanoglu I, Sozer O, Sezgin N, Kizilkilic E et al (2007) Platelet P-selectin expression in patients with sickle cell disease who undergone apheresis. Ther Apher Dial 11:255–261CrossRefPubMedGoogle Scholar
  25. 25.
    Karacaoglu PK, Asma S, Korur A, Solmaz S, Buyukkurt NT, Gereklioglu C et al (2016) East Mediterranean region sickle cell disease mortality trial: retrospective multicenter cohort analysis of 735 patients. Ann Hematol 95:993–1000CrossRefPubMedGoogle Scholar
  26. 26.
    Boga C, Ozdogu H (2016) Pregnancy and sickle cell disease: a review of the current literature. Crit Rev Oncol Hematol 98:364–374CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2017

Authors and Affiliations

  • Nurhilal Buyukkurt
    • 1
  • Ilknur Kozanoğlu
    • 2
  • Asli Pan Korur
    • 3
  • Suheyl Asma
    • 3
  • Mahmut Yeral
    • 1
  • Soner Solmaz
    • 1
  • Fatih Kandemir
    • 1
  • Cigdem Gereklioglu
    • 3
  • Cagla Sariturk
    • 4
  • Can Boga
    • 1
  • Hakan Ozdogu
    • 1
  1. 1.Department of HematologyBaskent University School of MedicineAnkaraTurkey
  2. 2.Department of PhysiologyBaskent University School of MedicineAnkaraTurkey
  3. 3.Department of Family MedicineBaskent University School of MedicineAnkaraTurkey
  4. 4.Biostatistics Specialist, Adana Research and Training CenterBaskent UniversityAdanaTurkey

Personalised recommendations